MolecularMD

The draft guidelines have intrigued industry players interested in pursuing labeling that would allow their CDx to direct treatment for a class of drugs instead of one drug.

The firms said they will integrate their capabilities and competencies to offer solutions to global pharmaceutical customers.

The tests from Asuragen and MolecularMD are designed for use in chronic myeloid leukemia patients, including those receiving tyrosine kinase inhibitor therapy.

The companion diagnostic test identifies patients taking the Novartis drug Tasigna who are candidates for treatment-free remission monitoring.

The test measures minimal residual disease and can be used to monitor patients eligible for discontinuation of treatment with Tasigna.

Promega's technology will be part of a larger portfolio of research products aimed at supporting oncology drug and clinical trial development.

The companies will work together to create an end-to-end workflow for biomarker and drug target validation, and assay development.

Researchers are using Bio-Rad's droplet digital PCR technology to validate seven ctDNA biomarkers that may predict melanoma recurrence.

The two companies have established a broad framework that will enable them to collaborate on specific projects to develop NGS-based companion diagnostics.

Pages

John Mendelsohn, a former president of the University of Texas MD Anderson Cancer Center, has died, the New York Times reports.

Chinese state news agency Xinhua reports that a preliminary investigation has found He Jiankui performed his gene-editing work illegally.

Identical twins receive different estimates of ancestry from the same direct-to-consumer genetic testing firms, CBC reports.

In PNAS this week: chromosomal features of maize, adaptations in the vinous-throated parrotbill, and more.